Company Profile
The Group are principally engaged in the manufacture and sale of edible collagen sausage casing products, collagen food products, collagen skin care products and polymer collagen medical biomaterials.
COLLAGEN SAUSAGE CASINGS
During 2024, the Group successfully developed and launched six new products of the collagen sausage casings series, namely “fried”, “crispy”, “fresh”, “tender”, “bright” and “colorful”, and held new product promotional seminars and global investment promotion seminars to initiate industry exchanges. The new products earned unanimous customer praise, laying a solid foundation for promoting the comprehensive upgrade of collagen sausage casings products and covering market needs. To cope with the launch of new products, the Group also constantly strengthened and improved its production capacity. The plan of production capacity expansion formulated by the Group has basically been achieved, with the production capacity of collagen sausage casings reaching 7 billion metres.
COLLAGEN FOOD PRODUCTS
During 2024, the Group launched new products such as “Bo Bo Chicken (缽缽雞)” and “Beef Tripe (牛西肚)” in the research and development of collagen food products, which were well received by the market. In addition, the Group upgraded its products such as “ready-to-eat beef tendon”, “collagen brown sugar ginger drink”, “collagen oat drinks” and “collagen oat porridge’, with the packaging and taste catering to the needs of consumers.
COLLAGEN SKINCARE PRODUCTS
For the research and development of collagen skincare products, the Group further increased its investment during 2024 by introducing a series of collagen skincare products, which have gradually enriched the product varieties and gained a favourable reputation. The development of collagen masks, skin nourishing lotions and multi-effective gel creams under the brands of “Luxianna”, “COLL-FULL”, “Collagen Family” and “coll-shine” has been improved and launched in the market gradually.
POLYMER COLLAGEN MEDICAL BIOMATERIALS
During 2024, the Group performed particularly well in the polymer collagen medical biomaterials segment, with the endotoxin content of the Group’s medical collagen raw materials extracted through its proprietary technology being only 0.01EU/ml, which is better than the FDA’s standard of 0.5EU/ml in the USA. The prospects of selling medical collagen raw materials were promising, representing an increase of 542.7% as compared with the Prior Year. Application has been made to the national regulatory authorities for the registration licence of “collagen bone filling biomaterials” as Class III medical device products, which is pending review and approval. The “oral post-operative medical collagen sponge (口腔術後醫用膠原蛋白海綿)” has passed the ethical review, and will enter the clinical trial stage. The “medical collagen dressing (醫用膠原蛋白敷料)” and “small beauty needle (小美容針)” are in the process of physicochemical indicators testing and animal trial.
